SciSparc Ltd. (NASDAQ:SPRC – Get Free Report)’s share price was down 11.3% on Thursday . The stock traded as low as $2.66 and last traded at $2.67. Approximately 57,396 shares were traded during trading, a decline of 82% from the average daily volume of 322,129 shares. The stock had previously closed at $3.01.
Wall Street Analyst Weigh In
Several research analysts have recently commented on SPRC shares. Wall Street Zen raised SciSparc to a “sell” rating in a report on Saturday, September 13th. Weiss Ratings restated a “sell (e+)” rating on shares of SciSparc in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, SciSparc currently has a consensus rating of “Sell”.
View Our Latest Research Report on SciSparc
SciSparc Price Performance
SciSparc Company Profile
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.
Recommended Stories
- Five stocks we like better than SciSparc
- Manufacturing Stocks Investing
- CAVA Stock Looking for Direction After Earnings Miss
- What is a Dividend King?
- 3 Small AI Stocks Ready to Explode (All Under $20)
- Best Stocks Under $10.00
- After 16% Fall, Analysts Eye a Big Recovery in Meta Platforms
Receive News & Ratings for SciSparc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciSparc and related companies with MarketBeat.com's FREE daily email newsletter.
